Pneumococcal Vaccines

Global Pneumococcal Vaccines Market to Reach US$11.3 Billion by 2030

The global market for Pneumococcal Vaccines estimated at US$8.3 Billion in the year 2024, is expected to reach US$11.3 Billion by 2030, growing at a CAGR of 5.3% over the analysis period 2024-2030. Pneumococcal Conjugate Vaccine, one of the segments analyzed in the report, is expected to record a 6.2% CAGR and reach US$7.4 Billion by the end of the analysis period. Growth in the Pneumococcal Polysaccharide Vaccine segment is estimated at 3.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.3 Billion While China is Forecast to Grow at 8.5% CAGR

The Pneumococcal Vaccines market in the U.S. is estimated at US$2.3 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$2.3 Billion by the year 2030 trailing a CAGR of 8.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.5% and 5.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.4% CAGR.

Global Pneumococcal Vaccine Market – Key Trends & Drivers Summarized

Why Is the Pneumococcal Vaccine Critical for Public Health?

Pneumococcal vaccines are essential in preventing infections caused by Streptococcus pneumoniae, a bacterium responsible for serious diseases such as pneumonia, meningitis, and sepsis. These infections pose a significant health risk, particularly to infants, young children, elderly individuals, and immunocompromised patients. The widespread adoption of pneumococcal vaccines has led to a substantial reduction in pneumococcal-related mortality and morbidity worldwide, reinforcing their importance in global immunization programs.

Governments and healthcare organizations, including the World Health Organization (WHO) and the Centers for Disease Control and Prevention (CDC), strongly advocate for routine pneumococcal vaccination to protect vulnerable populations. National immunization programs in high-income and developing countries have accelerated the uptake of pneumococcal conjugate vaccines (PCVs) and pneumococcal polysaccharide vaccines (PPSVs), significantly lowering infection rates. Additionally, the COVID-19 pandemic heightened awareness of respiratory infections, leading to increased demand for pneumococcal vaccination as part of broader public health initiatives to reduce complications from bacterial pneumonia in COVID-19 patients.

How Are Innovations in Vaccine Development Transforming the Market?

The pneumococcal vaccine market has evolved rapidly due to advancements in biotechnology, vaccine formulations, and immunization strategies. One of the most significant innovations is the development of next-generation pneumococcal conjugate vaccines (PCVs) with broader serotype coverage. Leading vaccine manufacturers, including Pfizer, Merck, and GlaxoSmithKline (GSK), have introduced multi-valent PCVs that offer protection against an expanded range of pneumococcal strains, addressing the challenge of emerging antibiotic-resistant and non-vaccine serotypes.

For instance, Pfizer’s PREVNAR 20 and Merck’s VAXNEUVANCE (PCV15) are next-generation vaccines designed to provide enhanced immunity against pneumococcal strains responsible for severe infections. These vaccines represent a major advancement over older formulations such as PREVNAR 13 and PCV10, which offered protection against fewer serotypes. Additionally, research into protein-based pneumococcal vaccines is gaining momentum, aiming to provide broader and more durable immunity against diverse pneumococcal strains.

Another transformative development in the market is the integration of mRNA vaccine technology in pneumococcal vaccine research. Inspired by the success of mRNA COVID-19 vaccines, companies are exploring mRNA-based pneumococcal vaccines that could offer quicker development timelines, improved efficacy, and adaptability against emerging serotypes. Such innovations have the potential to revolutionize pneumococcal disease prevention, especially in regions with high disease burdens.

Why Is Global Demand for Pneumococcal Vaccination Increasing?

The demand for pneumococcal vaccines is rising globally due to expanding immunization programs, aging populations, and increased awareness of respiratory infections. Countries with high infant mortality rates and a high burden of pneumococcal disease, such as those in Africa, South Asia, and Latin America, are scaling up vaccination efforts through partnerships with organizations like Gavi, the Vaccine Alliance, and the Global Pneumococcal Vaccination Initiative. These initiatives aim to improve vaccine access in low-income regions, significantly driving market expansion.

The aging global population is another critical factor fueling demand for pneumococcal vaccination. Older adults, especially those with underlying health conditions such as diabetes, chronic obstructive pulmonary disease (COPD), and cardiovascular diseases, face a heightened risk of pneumococcal infections. As a result, many countries have introduced adult pneumococcal vaccination programs, encouraging widespread immunization beyond childhood schedules. The rising prevalence of antimicrobial resistance (AMR) has further emphasized the need for preventive vaccination, as drug-resistant pneumococcal strains limit treatment options, making vaccination the most effective defense.

Additionally, the post-pandemic focus on respiratory health has accelerated pneumococcal vaccine uptake. Many public health agencies now recommend pneumococcal vaccination alongside flu and COVID-19 boosters for high-risk populations, integrating it into routine adult immunization programs. The pharmaceutical industry’s efforts to simplify dosing schedules and develop single-dose combination vaccines (e.g., pneumococcal vaccines combined with influenza or RSV vaccines) are expected to further drive uptake, particularly among elderly patients and immunocompromised individuals.

What Factors Are Driving the Growth of the Pneumococcal Vaccine Market?

The growth in the pneumococcal vaccine market is driven by several factors, including technological advancements, increasing global immunization coverage, and rising healthcare investments. One of the primary drivers is the expansion of pediatric and adult vaccination programs, supported by government policies and international funding initiatives. Countries are incorporating pneumococcal vaccines into routine immunization schedules, contributing to widespread market growth.

Another key factor is pharmaceutical innovation and competitive product development. Vaccine manufacturers are continuously enhancing their formulations to provide broader protection against evolving pneumococcal strains. The launch of multi-valent PCVs and combination vaccines is expected to shape the future of the market, offering longer-lasting immunity and reduced booster dose requirements. Additionally, investments in cold chain infrastructure and vaccine distribution networks are improving access to pneumococcal vaccines in remote and underserved regions.

The rising burden of pneumococcal diseases in emerging economies is also driving demand. Governments in countries like India, China, and Brazil are increasingly prioritizing pneumococcal vaccination as part of their public health strategies, leading to higher adoption rates. Additionally, corporate partnerships and public-private collaborations are helping reduce vaccine costs, making immunization more affordable for lower-income populations.

The growth of travel and medical tourism is another factor influencing the market. Many travelers, particularly those visiting regions with high pneumococcal disease prevalence, are opting for preventive vaccination, increasing demand in both developed and developing countries.

With ongoing innovations in vaccine technology, increasing awareness of pneumococcal disease prevention, and strong government and private sector support, the pneumococcal vaccine market is poised for steady expansion. As global healthcare priorities continue to shift toward preventive care and immunization, pneumococcal vaccines will remain a cornerstone of infectious disease prevention worldwide.

SCOPE OF STUDY:

The report analyzes the Pneumococcal Vaccines market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Vaccine Type (Pneumococcal Conjugate Vaccine, Pneumococcal Polysaccharide Vaccine); Product Type (Prevnar 13, Synflorix, Pneumovax 23, Vaxneuvance, Pneumosil, Other Product Types)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

• AIM Vaccine Co., Ltd.
• AstraZeneca
• Beijing Minhai Biotechnology Co., Ltd.
• Bharat Biotech International Ltd.
• Biological E. Limited
• CSL Limited
• Daiichi Sankyo Company, Limited
• Emergent BioSolutions Inc.
• GlaxoSmithKline plc (GSK)
• Merck & Co., Inc.
• Mitsubishi Tanabe Pharma Corporation
• Novartis International AG
• Panacea Biotec Ltd.
• Pfizer Inc.
• Sanofi
• Serum Institute of India Pvt. Ltd.
• Sinopharm Group Co., Ltd.
• Sinovac Biotech Ltd.
• Vaxcyte, Inc.
• Walvax Biotechnology Co., Ltd.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.